This is a summary of an article originally published in the journal Postgraduate Medicine.Lemborexant is a type of medication called a dual orexin receptor antagonist (often abbreviated to DORA) that is approved for treating people with insomnia, a sleep disorder in which people have trouble falling asleep, staying asleep or both. Two studies, one called SUNRISE-1 (Study 304), which lasted one month, and SUNRISE-2 (Study 303), which lasted 12 months, looked at the effects of lemborexant on sleep compared to placebo in people with insomnia. People with insomnia often experience fatigue (or tiredness) during the daytime, which affects their daily lives and health, and often have other conditions which can also cause fatigue. This summary reports an analysis that looked at whether lemborexant improves fatigue during the daytime as well as nighttime symptoms of insomnia in all participants and in participants with clinically significant fatigue before treatment.This Plain Language Summary of Publication article from Future Neurology summarises the results from two studies, SUNRISE-1 and SUNRISE-2, which looked at the effects of lemborexant on sleep in people with insomnia. This summary, specifically, looks at whether lemborexant improves fatigue during the daytime as well as improving nighttime symptoms.

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder’ and was published in Postgraduate Medicine

Visit Taylor & Francis Online using the link to read the original article.